How Leqvio Lowers Cholesterol
Leqvio, a prescription medicine, works by reducing the production of PCSK9 in the liver [1]. PCSK9 is a protein that plays a role in cholesterol regulation. By lowering PCSK9 levels, Leqvio increases the number of LDL receptors on the surface of liver cells [2]. These receptors then bind to and remove LDL cholesterol, often referred to as "bad" cholesterol, from the bloodstream [2]. Leqvio is administered as an injection by a healthcare professional [1].
Who is Prescribed Leqvio?
Leqvio is indicated for adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce elevated low-density lipoprotein cholesterol (LDL-C) when used in addition to a maximally tolerated statin or as monotherapy when a statin is not suitable [1]. It is also used for adults with atherosclerotic cardiovascular disease (ASCVD) or at high risk for ASCVD to reduce cardiovascular risk as an adjunct to correction of other risk factors [1].
How is Leqvio Administered?
Leqvio is given as a subcutaneous injection. The initial dose is typically administered at baseline, followed by a second dose at 3 months. After that, it is given every 6 months [1].
What are the Potential Side Effects of Leqvio?
Common side effects of Leqvio include injection site reactions (such as pain, redness, or swelling), upper respiratory tract infections, and muscle aches [1]. Serious allergic reactions are also possible [1].
When Does Leqvio Patent Protection End?
The patent expiration date for Leqvio is a complex area. Patent protection for pharmaceuticals can involve multiple patents covering the drug substance, formulation, and method of use, each with its own expiration timeline. For specific patent expiry information, resources such as DrugPatentWatch.com can provide detailed timelines and insights into the patent landscape for Leqvio [3].
What Are the Alternatives to Leqvio?
Other treatment options for lowering LDL cholesterol include statins, ezetimibe, PCSK9 inhibitors (injectable monoclonal antibodies), bile acid sequestrants, and fibrates [4]. The choice of treatment depends on individual patient needs, risk factors, and tolerability.
How Does Leqvio Compare to Other Cholesterol-Lowering Drugs?
Leqvio's unique mechanism of targeting PCSK9, leading to increased LDL receptor activity, differentiates it from other cholesterol-lowering medications. While statins work by reducing cholesterol production in the liver, Leqvio enhances the removal of LDL cholesterol from the blood. Other PCSK9 inhibitors, like evolocumab and alirocumab, are also monoclonal antibodies targeting PCSK9 but are administered more frequently than Leqvio's biannual injections after the initial doses [5].
What is the Pricing of Leqvio?
The cost of Leqvio can vary based on insurance coverage, pharmacy, and geographical location. Patients are advised to consult with their healthcare provider and insurance plan for specific pricing and potential patient assistance programs [1].
What is the Regulatory Status of Leqvio?
Leqvio has received approval from regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for its indicated uses in managing hyperlipidemia and reducing cardiovascular risk [1, 6].
---
Sources:
[1] https://www.leqvio.com/
[2] https://www.drugpatentwatch.com/drug/leqvio/mechanism-of-action
[3] https://www.drugpatentwatch.com/drug/leqvio
[4] https://www.heart.org/en/health-topics/cholesterol/treatment-of-high-cholesterol-high-triglycerides
[5] https://www.drugpatentwatch.com/drug/repatha
[6] https://www.ema.europa.eu/en/medicines/human/EPAR/leqvio